examined the role of Lorlatinib, a third‐generation anaplastic lymphoma kinase (ALK) inhibitor, in understanding the adaptive mechanisms underlying resistance to targeted agents through longitudinal tumor biopsy and ctDNA analysis using comprehensive molecular profiling. The gene discussed is ALK; the disease is neoplasm.